Research Article
Efficacy and Safety of Drug-Eluting Bead TACE in the Treatment of Primary or Secondary Liver Cancer
Table 1
Clinical information of unresectable primary liver cancer patients (n = 41).
| | Characteristics | Statistics |
| | Sex (male/female) | 37/4 | | Age (≥65 years old/<65 years old) | 20/21 | | Medical history | | | Hepatitis (yes/no) | 36/5 | | Alcohol (yes/no) | 3/38 | | Liver cirrhosis (yes/no) | 26/15 | | Tumor diameter (≥50 mm/<50 mm) | 25/16 | | Tumor number | 2.00 ± 1.70 | | Portal vein invasion (yes/no) | 5/36 | | ECOG (0/1/2) | 2/35/4 | | Child–Pugh (A/B) | 38/3 | | BCLC (A/B/C) | 16/18/7 | | Treatment history | | | Conventional TACE (yes/no) | 23/18 | | Surgery (yes/no) | 9/32 | | Ablation (yes/no) | 5/36 | | TKI drugs (yes/no) | 7/34 |
|
|
ECOG: Eastern Cooperative Oncology Group; BCLC: Barcelona clinical liver classification; TACE: transarterial chemoembolization; TKI: tyrosine kinase inhibitor.
|
